AlphaStocks
3.6
Weak

Doximity, Inc. (DOCS)

Health Care / Health Care Technology

S&P MidCap 400

$22.93

Scores poorly across most models. Proceed with caution.

Weak

Score based on 4 of 5 models — moderate confidence

#916out of 1127 in Health Care

Is Doximity, Inc. a Good Investment in 2026?

Doximity, Inc. (DOCS) scores 3.6 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates Doximity, Inc. as Strong (8/9). However, the Graham model rates it Caution — Significantly above fair value. Doximity, Inc. currently trades below its estimated fair value of $32, suggesting potential upside. Doximity, Inc. ranks #916 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E20.7ROE21.1Market Cap5B

Estimated Fair Value

$32.1229% below

Fair value above market price. EPS grew 55% year-over-year. ROE of 21% signals strong profitability. P/E of 21x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Attractive

PEG 1.2 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Doximity, Inc. (DOCS) a good investment?
Based on AlphaStocks' composite analysis, Doximity, Inc. (DOCS) scores 3.6 out of 10, earning a Weak rating. This score is below average, suggesting caution. Fair value above market price. EPS grew 55% year-over-year. ROE of 21% signals strong profitability. P/E of 21x is moderate for this quality level.
What is Doximity, Inc.'s Piotroski F-Score?
Doximity, Inc.'s Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is DOCS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $32, DOCS appears undervalued. The stock currently trades 29% below its estimated fair value. Fair value above market price. EPS grew 55% year-over-year. ROE of 21% signals strong profitability. P/E of 21x is moderate for this quality level.
How does DOCS compare to other Health Care stocks?
Doximity, Inc. ranks #916 out of 1127 stocks in the Health Care sector, placing it in the top 81% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about DOCS?
AlphaStocks evaluates DOCS using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Attractive. These models are combined into a single composite score of 3.6/10.

Similar Stocks

PARRFTIAZN

Compare DOCS with

DOCS vs PARRDOCS vs FTIDOCS vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer